Hana Biosciences Announces Second Quarter and Six Month 2007 Results


SOUTH SAN FRANCISCO, Calif., Aug. 6, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced financial results for the three and six months ended June 30, 2007.



 -- Non-GAAP net loss of $7.3 million for the three months ended June
    30, 2007 compared to $6.5 million for the three months ended June
    30, 2006; GAAP net loss was $9.1 million for the three months ended
    June 30, 2007, which included a $1.8 million charge related to
    SFAS 123R employee stock-based compensation expense(1), compared
    to $20.7 million for the three months ended June 30, 2006.  The
    GAAP net loss for 2006 included an $11.9 million one-time charge
    related to the accounting treatment of the company's acquisition
    of product candidates from Tekmira Pharmaceuticals Corp. and a
    $2.3 million charge related to FAS 123R employee stock-based 
    compensation expense (1,2).

 -- Non-GAAP net loss of $13.2 million for the six months ended June
    30, 2007 compared to $9.7 million for the six months ended June
    30, 2006; GAAP net loss was $17.3 million for the six months ended
    June 30, 2007, which included a $4.1 million charge related to
    SFAS 123R employee stock-based compensation expense (1), compared
    to $24.1 million for the six months ended June 30, 2006.  The GAAP
    net loss for 2006 included an $11.9 million one-time charge related
    to the accounting treatment of the company's acquisition of product
    candidates from Tekmira Pharmaceuticals Corp. and a $2.5 million 
    charge related to SFAS 123R employee stock-based compensation 
    expense (1,2).

 -- Cash used in operations was $14.0 million for the six months ended
    June 30, 2007. Hana ended the quarter with approximately $21.0
    million in cash and cash equivalents and short-term investments.

"We are thrilled that our rebuilding efforts in the first half of the year have successfully allowed Hana Biosciences to begin a strong charge forward in the second half of 2007," said Mark J. Ahn, Ph.D., President and CEO of Hana. "We have some ambitious goals for the remainder of the year, and are pleased to have already achieved a great deal by finding a strong partner in Par Pharmaceutical for Zensana and initiating enrollment in our registration program for Marqibo."

A reconciliation (2) between non-GAAP and GAAP earnings per share for the second quarter and year to date 2007 and 2006 is provided in the following table:



 ---------------------------------------------------------------------
              Reported       Employee        Costs         Non-GAAP
             GAAP/Basic       Stock        Associated      Basic and
             and Diluted   Compensation    with Tekmira   Diluted EPS
                EPS          Expense       Acquisition
 ---------------------------------------------------------------------
 Q2 2007       ($0.31)         $0.06          $0.00          ($0.25)
 ---------------------------------------------------------------------
 Q2 2006       ($0.81)         $0.09          $0.48          ($0.26)
 ---------------------------------------------------------------------
 YTD 2007      ($0.59)         $0.14          $0.00          ($0.45)
 ---------------------------------------------------------------------
 YTD 2006      ($1.00)         $0.11          $0.50          ($0.41)
 ---------------------------------------------------------------------
 Note: Amounts may not sum due to rounding.

2007 Progress to Date



 * Marqibo(r) received Orphan Drug Designation, allowing a potential
   accelerated approval registration pathway in adult acute
   lymphoblastic leukemia (ALL).
 * Alocrest(tm) Phase 1 is currently enrolling its fourth dosing cohort
   and is proceeding on track.
 * Hana presented data in two general poster sessions at the 43rd
   Annual American Society of Clinical Oncology (ASCO) Annual Meeting.
 * Lyn Wiesinger joined Hana's Board of Directors and Leon E. Rosenberg
   was named Chairman of the Board.
 * Steven R. Deitcher, M.D. was appointed as its Executive Vice
   President and Chief Medical Officer.
 * Hana announced the licensing of North American commercial rights
   for Zensana(tm) to Par Pharmaceuticals.
 * Hana initiated the Marqibo(r) relapsed ALL clinical trial.

Hana Biosciences' management will host a conference call discussion today at 5:00pm EDT, 2:00pm PDT. Those interested in hearing management's discussion may join the call by dialing (877) 407-8031 in the U.S./Canada. International participants may access the call by dialing (201) 689-8031. A replay of this call will be available for one month by dialing (877) 660-6853 U.S./Canada and (201) 612-7415 for International participants. When prompted, enter Account Number #286 and Conference ID #249279. Participants may also access a webcast of the conference call Hana's website at www.hanabiosciences.com.

Reconciliation of GAAP to Non-GAAP Net Loss

GAAP refers to generally accepted accounting principles in the United States of America. Hana's non-GAAP net loss and loss per share excludes the impact of stock option expense related to the implementation of SFAS 123R. Hana is reporting non-GAAP results in addition to, and not as a substitute for, financial measures calculated in accordance with GAAP. Hana provides these non-GAAP numbers to facilitate a comparison of its business from period to period and to allow investors to analyze its business results using the same measures Hana's management uses to evaluate the company's operating performance. Investors are encouraged to carefully consider Hana's results under GAAP, as well as the non-GAAP reconciliation between these presentations, to more fully understand our business.



 (1) On January 1, 2006, the Company adopted Statement of Financial
     Accounting Standards No. 123R (or SFAS 123R) using the  modified
     prospective for share-based awards granted after the Company
     became a public entity and the prospective basis for share-based
     awards granted prior to the Company becoming a public entity.

 (2) Hana's non-GAAP net loss and non-GAAP loss per share excludes the
     impact of the one-time upfront fees paid to Tekmira Pharmaceuticals
     and transaction fees paid as part of its acquisition of three
     product candidates. The differences in non-GAAP and GAAP numbers
     are reconciled in the accompanying tables.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.

The Hana Biosciences, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3290

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include without limitation, statements regarding the timing, progress and anticipated results of the clinical development, regulatory processes, potential clinical trial initiations, potential IND and NDA filings and commercialization efforts of Hana's product candidates, including its Marqibo product candidate. Such statements involve risks and uncertainties that could cause Hana's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Hana's development efforts relating to its other product candidates will be successful, that Hana will be able to obtain regulatory approval of any of its product candidates, and that the results of clinical trials will support Hana's claims or beliefs concerning the effectiveness of its product candidates. Additional risks that may affect such forward-looking statements include Hana's need to raise additional capital to fund its product development programs to completion, Hana's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission. Hana assumes no obligation to update these statements, except as required by law.



                         HANA BIOSCIENCES, INC.
                      (A DEVELOPMENT STAGE COMPANY)

                        CONDENSED BALANCE SHEETS


                                              June 30,     December 31,
                                               2007           2006
 ASSETS                                     (Unaudited)

 Current assets:
 Cash and cash equivalents                 $ 14,368,012   $ 29,127,850

 Available-for-sale securities                6,590,494      6,131,000
 Prepaid expenses and other
   current assets                               441,399        496,519
                                           ------------   ------------  
  Total current assets                       21,399,905     35,755,369

 Property and equipment, net                    417,885        424,452
 Restricted cash                                125,000        125,000
                                           ------------   ------------
 Total assets                              $ 21,942,790   $ 36,304,821
                                           ============   ============

 LIABILITIES AND STOCKHOLDERS' EQUITY

 Current liabilities:
 Accounts payable                          $  3,193,112   $  2,739,956
 Accrued expenses                               570,007      1,547,459
 Accrued personnel related expenses             742,738      1,050,657
 Accrued research and development costs         366,984        596,927
                                           ------------   ------------
 Total current liabilities                    4,872,841      5,934,999

  Commitment and contingencies:

 Stockholders' equity:
 Common stock; $0.001 par value:
 100,000,000 shares authorized,
   29,485,283 and 29,210,627 shares
   issued and outstanding at June 30,
   2007 and December 31, 2006,
   respectively                                  29,485         29,211
 Additional paid-in capital                  97,171,024     93,177,445
 Accumulated other comprehensive income              --         20,000
 Deficit accumulated during the
   development stage                        (80,130,560)   (62,856,834)
                                           ------------   ------------
 Total stockholders' equity                  17,069,949     30,369,822
                                           ------------   ------------
 Total liabilities and
   stockholders' equity                    $ 21,942,790   $ 36,304,821
                                           ============   ============




                       HANA BIOSCIENCES, INC.
                   (A DEVELOPMENT STAGE COMPANY)

     CONDENSED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS
                              (Unaudited)



                     Three Months Ended           Six Months Ended
                         June 30,                     June 30,
                    2007          2006          2007          2006
 Operating
   expenses:
 Selling,
   General and
   administra-
   tive         $  2,725,362  $  2,576,308  $  6,072,347  $  3,560,283
 Research and
   development     6,473,793    18,368,374    11,711,697    20,946,506
                ------------  ------------  ------------  ------------

 Total operating
   expenses        9,199,155    20,944,682    17,784,044    24,506,789

 Loss from
   operations     (9,199,155)  (20,944,682)  (17,784,044)  (24,506,789)
                ------------  ------------  ------------  ------------
 Other income
   (expense):
 Interest
   income, net       313,392       249,426       704,958       384,752
 Other expense,
   net              (189,388)       (8,800)     (194,640)      (16,692)
                ------------  ------------  ------------  ------------
 Total other
   income
   (expense)         124,004       240,626       510,318       368,060
                ------------  ------------  ------------  ------------
 Net loss       $ (9,075,151) $(20,704,056) $(17,273,726) $(24,138,729)
                ============  ============  ============  ============
 Net loss per
   share, basic
   and diluted  $      (0.31) $      (0.81) $      (0.59) $      (1.00)
                ============  ============  ============  ============
 Shares used
   in computing
   net loss
   per share,
   basic and
   diluted        29,383,420    25,640,398    29,334,829    24,037,103
 Comprehensive
   loss:
 Net loss       $ (9,075,151) $(20,704,056) $(17,273,726) $(24,138,729)
 Unrealized
   gain (loss)       116,000      (156,000)      (20,000)       68,000
                ------------  ------------  ------------  ------------
 Comprehensive
   loss         $ (8,959,151) $(20,860,056) $(17,293,726) $(24,070,729)
                ============  ============  ============  ============


                                                     Cumulative
                                                     Period from
                                                     December 6,
                                                    2002 (date of
                                                    inception) to
                                                       June 30,
                                                         2007

 Operating expenses:
 Selling, General and administrative             $     23,712,291
 Research and development                              58,373,740
                                                 ----------------
 Total operating expenses                              82,086,031
 Loss from operations                                 (82,086,031)
                                                 ----------------
 Other income (expense):
 Interest income, net                                   2,276,534
 Other expense, net                                      (321,063)
                                                 ----------------
 Total other income (expense)                           1,955,471
                                                 ----------------
 Net loss                                        $    (80,130,560)
                                                 ================


            

Kontaktdaten

GlobeNewswire